stopping semaglutide after weight loss Let’s Stop the Shame: A Compassionate Look at Medications People who stop weight loss

Regional Insights North America GLP-1 Receptor Agonist Market Trends North America dominates the GLP-1 receptor agonist market with a 41.8% share in 2025 , driven by the high prevalence of diabetes and obesity, coupled with strong healthcare infrastructure and widespread insurance coverage

Sherwell Biotech PCD pharma franchise, best PCD pharma company in India, monopoly pharma franchise company, pharma franchise opportunity, pharmaceutical distributorship business, medicine franchise company, ethical pharma franchise, PCD medicine supplier, pharma products manufacturer and supplier, third-party pharma manufacturing company, PAN India pharma franchise, low-investment pharma business, pharmaceutical marketing company, pharma franchise for distributors, pharma monopoly rights and PCD franchise business opportunity

It also causes temporary (3 months) paralysis of the muscle being innervated by those nerve endings

von Scholten BJ, Kreiner FF, Rasmussen S, Rossing P, Idorn T (2022) The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice

Such a risk was confirmed by a meta-analysis recruiting 26 published studies which showed an association between MTHFR C677T polymorphism and increased risk of depression 73